They also showed that treatment with AD-MSC-derived EVs decreases IL-4 and IL-5 levels in the lungs, but not IL-13 or eotaxin levels that were decreased by treatment with AD-MSCs, in experimental allergic asthma. The gene discussed is IL4; the disease is Alzheimer disease.